Substance abuse and pharmacy practice: what the community pharmacist needs to know about drug abuse and dependence by Tommasello, Anthony C
BioMed  Central
Page 1 of 15
(page number not for citation purposes)
Harm Reduction Journal
Open Access Review
Substance abuse and pharmacy practice: what the community 
pharmacist needs to know about drug abuse and dependence
Anthony C Tommasello*
Address: University of Maryland School of Pharmacy, Office of Substance Abuse Studies, USA
Email: Anthony C Tommasello* - atommase@rx.umaryland.edu
* Corresponding author    
Abstract
Pharmacists, the most accessible of health care professionals, are well positioned to help prevent
and treat substance use disorders and should prepare themselves to perform these functions. New
research improves our knowledge about the pharmacological and behavioral risks of drug abuse,
supports the clinical impression that drug dependence is associated with long-lasting neurochemical
changes, and demonstrates effective pharmacological treatments for certain kinds of drug
dependencies. The profession is evolving. Pharmacists are engaging in new practice behaviors such
as helping patients manage their disease states. Collaborative practice agreements and new federal
policies set the stage for pharmacists to assist in the clinical management of opioid and other drug
dependencies. Pharmacists need to be well informed about issues related to addiction and prepared
not only to screen, assess, and refer individual cases and to collaborate with physicians caring for
chemically dependent patients, but also to be agents of change in their communities in the fight
against drug abuse.
At the end of this article the pharmacist will be better able to:
1. Explain the disease concept of chemical dependence
2. Gather the information necessary to conduct a screen for chemical dependence
3. Inform patients about the treatment options for chemical dependence
4. Locate resources needed to answer questions about the effects of common drugs of abuse
(alcohol, marijuana, narcotics, "ecstasy", and cocaine)
5. Develop a list of local resources for drug abuse treatment
6. Counsel parents who are concerned about drug use by their children
7. Counsel individuals who are concerned about drug use by a loved one.
8. Counsel individuals who are concerned about their own drug use
Introduction
Given the ongoing public attention paid to the problems
of substance abuse and chemical dependence in American
society, it is somewhat disappointing that few health care
professionals are educated and trained in this area of clin-
ical care [1]. Pharmacists are front-line health care
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providers and arguably are the most accessible members
of a health care team. They are expected to play a multi-
tude of roles – custodian of the country's legitimate sup-
ply of Schedule II drugs, purveyor of clean needles in
harm reduction public health endeavors, dispenser of
addictions pharmacotherapy, provider of drug informa-
tion, and drug educator – to name some of the more visi-
ble functions. Yet few pharmacists are adequately
informed or prepared to assume these diverse functions as
they relate to issues of substance abuse and chemical
dependence [2].
While science has moved forward and clinical methods
have improved, the drug abuse problem has grown more
complex. No longer can we think in terms of a person
being addicted to one drug or another. Rather it is fre-
quently the case that an individual uses many different
drugs often in combination. The issue is further compli-
cated by the co-occurrence of substance abuse and mental
illness. Even seasoned specialists find it difficult to disen-
tangle the web of causation when the two conditions co-
exist in one patient. It is clear that these are synergistic
pathologies each exacerbating the symptoms of the other.
Stereotypes established decades ago continue to shape
perceptions of "the drug problem" despite dramatic scien-
tific advances in substance abuse research over the past 20
years. It is now well established and widely accepted that
addiction is a brain disease [3] and that effective interven-
tions properly deployed reduce the consequences of
addiction for the individual and for society. Clinical tech-
niques for screening and assessment have been shown to
identify individuals who are likely to have the disease and
to determine their treatment needs. Treatment tech-
niques, including pharmacotherapy, have become more
specialized and the rates of recovery among various seg-
ments of chemically dependent patients have improved.
For instance, we know that 25% of alcoholic patients
remain constantly abstinent during the year after treat-
ment and an additional 10% significantly reduce alcohol
consumption [4].
Surveys conducted in the United States on a regular basis
[5] reveal a trend in which young people start experiment-
ing with alcohol and illicit drugs earlier in life today than
in years past. The list of "drugs of abuse" has expanded
such that drugs easily available to the middle school stu-
dent today were unknown or non-existent only ten years
ago. Adolescence is an especially risky period of life for
substance abuse involving powerful mind-altering drugs.
Parents are justified in their fear and concern for the well
being of their children.
Pharmacists may find themselves ill prepared to respond
effectively when approached by patients, parents, and
civic leaders who look to our profession for expertise in
this area. Since substance abuse has been a somewhat
arcane specialty area, health professionals for the most
part have not been expected to possess a working knowl-
edge of this issue. The coverage of the topic in health pro-
fessions training programs has typically been superficial
across the country [6]. However, recent legislation [7]
passed by Congress is bringing the treatment of opiate
addiction out of specialty clinics and into the offices of
general practitioners. Pharmacists must understand sub-
stance abuse and chemical dependence at least as well as
they understand other diseases.
What is addiction and how do people get it?
Addiction is a chronic, primary, progressive and fatal dis-
ease characterized by the compulsion to use drugs, with
an associated loss of control over drug use, and continued
use of drugs despite known problems [7]. More specific
diagnostic criteria for a variety of individual substance
related disorders are found in the DSM-IV [8] manual.
Compulsion involves an inability to resist the desire to
use a drug. Thus while most people let the thought of hav-
ing a drink simply pass through their consciousness, for
alcoholics the thought is an undeniable need that must be
satisfied.
Loss of control is best understood as the inability to use in
moderation consistently. For the average person, quitting
after one, two, or three drinks is not a struggle. The alco-
hol-dependent drinker may plan to stop after just a few
drinks, and occasionally may succeed, but it is with some
effort. Repeated episodes of social drinking increase the
risk that the alcohol dependent person will succumb to
another incident of excessive drinking with subsequent
adverse consequences. Thus, the stereotype of a constantly
intoxicated daily user represents a small segment of drug
dependent people.
Continued use despite problems can be misinterpreted as
simply the repeated exercise of poor judgment. Unfortu-
nately, by the time substance abusers have developed full-
blown chemical dependence, they have constructed a wall
of denial around themselves. Their perception of reality is
twisted into the belief that drug use is the result of their
misfortune. Rather, it is the frequent abuse of substances
that leads to repeated negative consequences in their lives.
Disrupted interpersonal relations, poor job performance,
low self-esteem, and eventual ill health are the sequelae of
substance abuse and, taken together, may evolve into a
perverted justification for self-medication.
While the question of the magnitude of the problem
appears to be simple, answers vary according to how the
estimate is made. One must distinguish between sub-
stance abuse and substance dependence, factor inHarm Reduction Journal 2004, 1 http://www.harmreductionjournal.com/content/1/1/3
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differences among chemicals, consider regional varia-
tions, and recognize market specificity for particular illicit
drugs. Using DSM-IV criteria, the bulk of epidemiological
studies puts the figure for alcohol dependence at 13% to
18% of the American population [10]. The rates for other
drugs except for tobacco are lower on a national basis,
while the rate of abuse is higher overall than the rate of
dependence for any particular substance.
The "brain disease" view of addiction is supported by
studies indicating that the brains of chemically dependent
individuals are different from others in many important
ways. The brain reward system is the center of attention of
much of the new thinking about the disease of addiction.
In the healthy brain this system reinforces human (and
animal) behaviors that are life sustaining. Brain cells
adapt to the introduction of chemicals and it is theorized
that excessive bombardment of this system by drugs pro-
duces dysfunctional adaptations that become embedded
in the neuronal circuitry [11]. Alan Leshner of the
National Institute on Drug Abuse summarizes these dif-
ferences as follows: "The addicted brain is distinctly differ-
ent from the non-addicted brain, as manifested by
changes in brain metabolic activity, receptor availability,
gene expression, and responsiveness to environmental
cues" [3]. Researchers conclude that constant drug use
establishes new patterns of neuronal firing in the centers
of the brain reward system so that the addicted brain is
functionally and morphologically different from a non-
addicted brain. For example, an addict responds to visual,
olfactory, and auditory cues very differently than a non-
addict. Thus, a line of white powder, the aroma of mari-
huana smoke, or a particular piece of music is associated
with specific drug use behaviors for the addict, but for the
non-addict these same cues carry no special meaning.
Risk factors for addiction have been identified. Genetic
predisposition is generally regarded as a strong predictor
for eventual disease. Thus, while the general population
risk for alcoholism is about 13%, the risk hovers around
50% for sons of alcoholic fathers [12]. There is also a gen-
der bias; males are more at risk than females [13]. Of
course, the risk of addiction is stronger for some drugs
than for others. One measure of the addiction potential of
drugs is captured in the proportion of those who experi-
ment with a drug who eventually become compulsive
users at some point in their lives. Using this measure, the
most addictive behavior is cigarette smoking that claims
40% to 60% of those who try cigarettes. Following ciga-
rette smoking is cocaine abuse, wherein about 30% to
50% of experimenters become chemically dependent.
Heroin addiction occurs in about 25% to 40% of experi-
menters. Alcohol addiction occurs in about 13% to 18%
of those who experiment with it, while marijuana addic-
tion occurs in about 6% to 9% of users [14,15].
While cocaine, heroin, and marijuana capture much
media attention, studies confirm that tobacco and alcohol
claim many more lives. Cigarette smoking accounts for
400,000 deaths annually and is considered the single
most preventable cause of death in American. Alcohol-
related deaths total about 100,000 and the remaining ille-
gal drugs of abuse claim about 20,000 deaths per year for
all drugs combined [16].
Why should pharmacists screen patients for 
substance use and addiction?
The goal of pharmacy education and training is to prepare
clinicians for practice in a complex and demanding thera-
peutic environment. Pharmaceutical care is defined as:
"the direct, responsible provision of medication-related
care for the purpose of achieving definite outcomes that
improve a patient's quality of life. The principal elements
of pharmaceutical care are that care is directly provided to
the patient, it is provided to produce definite outcomes,
these outcomes are intended to improve the patient's
quality of life and the provider (pharmacist) accepts per-
sonal responsibility for the outcomes."[17]
The American Pharmacists Association takes a similar
position by stating: "The mission of Pharmacy is to serve
society as the profession responsible for the appropriate
use of medications, devices and services to achieve opti-
mal therapeutic outcomes" [18]. To fulfill these goals,
pharmacists must acquire a complete drug history for all
patients under their care. It is considered routine practice
to ask patients about prescription and over-the-counter
medications, and in recent years, the importance of herbal
product use has become apparent. However, it is doubtful
that pharmacists routinely ask about nicotine or alcohol
use and more unlikely that they question patients about
illicit drug use. Yet these psychoactive chemicals exert
powerful pharmacological effects, are known to be
involved in a host of drug interactions, and have the
capacity to provoke profound behavioral priorities. The
failure to elicit information from patients about these
drugs is an obvious omission in an otherwise comprehen-
sive medication use history.
Cigarette use is associated with and exacerbates cardiovas-
cular and pulmonary dysfunction. Nicotine is a vasopres-
sor and cardiac stimulant, and smoke is an obvious
pulmonary irritant. Thus, in the short run, any patient
receiving prescription medication for any cardiovascular
or pulmonary condition should be screened for tobacco
use. Smokers need unambiguous information about the
association between their tobacco use and their medical
problem. However, asking about tobacco use should not
be limited to patients with these medical conditions.Harm Reduction Journal 2004, 1 http://www.harmreductionjournal.com/content/1/1/3
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Guidelines developed by the Agency for Healthcare
Research and Quality (AHRQ) stress the public health
gains that can be achieved by questioning all patients
about tobacco use and advising all smokers to quit [19].
Recent evidence suggests that pharmacists' advice to quit
smoking can produce significant increases in quit rates
among smokers [20]. Therefore, even when a patient's
condition is unrelated to tobacco use, giving up smoking
will improve the health of all smokers, and the health of
their families will be improved by eliminating second
hand smoke in the household.
There is a wealth of literature on nicotine pharmacology,
tobacco use, and smoking cessation [21]. More detail on
these facets of nicotine is readily accessible, and the evi-
dence to justify pharmacists asking about tobacco use is
strong. For the pharmacist who wants to build a practice
around smoking cessation, certification programs are
available.
Asking about alcohol use and screening for dependence
can provide vital data for optimizing pharmacotherapy
outcomes. Alcohol use should be avoided with many pre-
scription medications [22]. While pharmacists are likely
to provide ancillary labels warning patients about drug/
alcohol interactions, can they assume the label is a suffi-
cient deterrent to alcohol use? Although there are no data
to answer this question directly, this author assumes that
the warning is sufficient for those who use alcohol occa-
sionally and who can abstain from drinking without diffi-
culty. For the alcohol-dependent patient this warning may
be impossible to heed. Special interventions will be
needed to avoid potentially serious drug/alcohol interac-
tions in an alcohol dependent patient.
The clinical ramifications of alcohol dependence run
deeper than the acute problem of drug/alcohol interac-
tions. A patient with alcohol (or any other chemical)
dependence is operating under a set of life priorities that
are different from those who are not chemically depend-
ent. For the vast majority of patients dealing effectively
with their illness, taking medications according to the
doctor's order should be a top priority. However, even in
the general population, non-adherence to prescription
drug administration schedules has been estimated to be
on average 50% with a range of from 10% to 90% and is
a likely cause of outpatient prescription drug failure [23].
One cause of prescription drug non-compliance is drug
abuse. For instance, drug abuse is known to be associated
with non-adherence to Highly Active Anti-Retroviral Ther-
apy (HAART) [24]. The extent of non-adherence to other
prescription medications that can be attributed to chemi-
cal dependence is unknown, but the issue cannot be
addressed at all unless those at risk of alcohol or other
drug dependence are identified.
Asking about the use of illegal drugs and screening for
dependence on these chemicals is a daunting task. One
must first establish a professional belief that these ques-
tions are driven by therapeutic concerns and dispel hesita-
tion created by feeling that one is intruding into a
forbidden area of another's life. The concerns regarding
drug interactions and life priorities discussed in relation
to alcohol use are equally of concern in the case of illicit
drug use and dependence. However, the stigma associated
with illicit drug use is greater than that associated with
alcohol or nicotine use. Therefore, the pharmacist must
proceed with sensitivity, respect, and confidentiality.
Patients should understand that the questions are routine
and that honest answers are critical to the safe and effec-
tive use of their prescription medication.
Any drug history should be conducted in as confidential
an atmosphere as possible in the practice environment.
These are basic professional concerns heightened to the
level of potential legal liability with the introduction of
the Health Insurance Portability and Accountability Act of
1996 (HIPAA). Given the likelihood that patients will be
hesitant to answer questions about drug use in an open
area, facilities for private discussion should be provided
when it is evident that the therapeutic conversation
includes sensitive areas of a person's history. Assurance of
confidentiality can allay patient fears related to disclosure
of personal information.
How can pharmacists screen patients for 
substance abuse and addiction?
Asking about non-therapeutic drug use and screening for
chemical dependence are two separate activities with dif-
ferent therapeutic goals. A thorough accounting of a per-
son's non-therapeutic drug use can mitigate drug
interactions if the patient can comply with a pharmacist's
warnings concerning mixing alcohol or other substances
with prescription medication. Some patients conform to
this advice because they are not compulsive drug users
and can exert control over their drug use when convinced
of the necessity to abstain.
The AHRQ recommends that all patients be asked about
tobacco use at every visit. In effect, tobacco use should be
treated as a vital sign and smoking status should be ascer-
tained at the first visit as "non-smoker", "former smoker"
or "current smoker." These choices should be incorpo-
rated as check off options on the drug history form in the
pharmacy computer. Since adult non-smokers are
unlikely to initiate smoking in later life this group need
not be asked repeatedly. Former smokers are always at risk
of relapse and thus should be questioned periodically
about their status and given positive feedback for sustain-
ing abstinence. All current smokers should be advised
with each visit to quit smoking for the benefit of theirHarm Reduction Journal 2004, 1 http://www.harmreductionjournal.com/content/1/1/3
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health and guided to effective therapies if they acknowl-
edge a desire to quit.
Asking about alcohol use requires a bit more finesse. An
opening question such as "How do you use alcohol?" is
non-threatening and unlikely to be regarded as being
intrusive. Preceding this question with a statement regard-
ing the duty of pharmacists to warn patients about unto-
ward drug reactions and the confidentiality of the
information will emphasize the protected nature of the
conversation and its therapeutic intent. "It's important for
your safety that you tell me the truth about this" is lan-
guage emphasizing the practical reason for your ques-
tions. Asking about illegal drugs is a more sensitive issue
and one may initially be hesitant to venture into this area
of questioning. After ascertaining tobacco use and alcohol
use, a natural follow-up question is "Do you take any
other kinds of drugs?".
Clearly, patients should be cautioned to refrain from all
tobacco, alcohol, and illegal drug use while taking pre-
scription medication when the combination would be
harmful. It is also clear that some patients will not be able
to conform to this behavioral change. "If you find that
you are unable to refrain from drug use during the period
of prescription therapy, I strongly recommend that you
seek assistance" is a statement that could spark a turning
point in the life of individuals who otherwise may feel in
total control of their drug use. A brochure on this subject
can effectively convey the message while insuring
confidentiality.
The issue of screening for addiction as a practical activity
for the dispensing pharmacist may stimulate much
debate. In the busy environment of the community phar-
macy, there is little time to fulfill the required aspects of
dispensing, much less to take on additional tasks. How-
ever, the same has been said about most other health prac-
tice settings. Screening strategies have been developed for
use in today's hectic and fast paced health care delivery
environment. CAGE is an example of the extent to which
questions can reliably screen for alcoholism. The ques-
tions are:
1. Have you ever felt the need to Cut down on your
drinking?
2. Have you ever been Annoyed by criticism of your
drinking?
3. Have you ever felt Guilty about your drinking?
4. Have you ever needed an Eye opener (a morning drink)
to steady your nerves, get rid of a hangover, or get the day
started?
Since CAGE is a screening tool it cannot render a diagno-
sis and is not a substitute for a thorough assessment. How-
ever, a single "yes" response is considered a positive screen
and should trigger a referral to a substance abuse specialist
for a full assessment [25]. Some critics have felt that ques-
tions should screen for both alcohol and other drugs and
for abuse as well as dependence. Two questions have
emerged that address these issues: 1)"Have you ever felt
you wanted or needed to cut down on your drinking or
drug use in the last year?", and 2)"In the last year have you
ever drunk or used drugs more than you meant to?" A
"yes" to either question is a positive screen [26]. Williams
and Vinson have further distilled the screening for prob-
lem drinking to one question. "When was the last time
you had more than 5 drinks (4 for women) in one day?"
Problem drinking, defined as either past-month hazard-
ous drinking or past-year DSM-IV alcohol use disorder
[9], is considered present in anyone who answers the
question with a date that falls within the last 3 months
[27].
What do patients need to know about addiction 
treatment?
Patients need to know how their medications work and
what the role of medication is in the treatment of chemi-
cal dependence. The increasing emphasis being placed on
training physicians to screen, assess, and treat chemical
dependence, coupled with new policies and advances in
addiction pharmacotherapy predicts that a larger propor-
tion of substance abusers and chemically dependent
patients will receive treatment. Many of them will bring
prescriptions related to their outpatient management into
community pharmacies across the country. From nicotine
transdermal patches used in the treatment of tobacco
addiction, to disulfiram and naltrexone for alcoholism, to
buprenorphine for the treatment of opioid dependence,
outpatient pharmacotherapy for addiction is becoming
more commonplace. Patients need counseling related to
these therapies as much as for other disease states.
The passage of the Drug Addiction Treatment Act by the
U.S. Congress in 2000, coupled with the approval by the
Food and Drug Administration in October 2003 of
buprenorphine sublingual tablets for the treatment of
opioid dependence (Subutex ® and Suboxone ®), may
make this a routine prescription intervention. Pharmacists
should become familiar with the fundamental biological
facts related to opioid dependence and the pharmacother-
apeutic approaches for medical withdrawal and mainte-
nance [28].
Table 1 lists the agents currently approved by the Food
and Drug Administration for the outpatient treatment of
tobacco, alcohol, and opioid addiction. Details on the
pharmacology and use of these medications are availableHarm Reduction Journal 2004, 1 http://www.harmreductionjournal.com/content/1/1/3
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from usual compendia on prescription products. No pre-
scription medications are currently approved for the out-
patient treatment of chemical dependence to other drugs
such as marijuana or cocaine.
Patients should understand that medication alone is
insufficient for the long-term successful treatment of
chemical dependence. For addiction pharmacotherapy,
the medication is an adjunct in an overall treatment pro-
gram. The goals of addiction pharmacotherapy are to
achieve and/or sustain abstinence from the patient's drug
of choice. Patients should be informed that their active
participation in a comprehensive program of recovery is
expected of them. Thus, in addition to abstinence from
their drug of choice, patients should make adjustments in
their lives that promote abstinence and reduce their expo-
sure to situations associated with their drug abuse. These
kinds of lifestyle changes are best achieved with a program
of counseling and by building relationships with others
who have dedicated themselves to a life of sobriety.
These non-pharmacological interventions represent the
"Achilles heel" in addiction treatment. They are part of the
recovery process often overlooked or ignored by both
patients and health care providers. The well-informed cli-
nician recognizes that this focus is as vital to the success of
addiction treatment as is, for example, blood glucose
monitoring and diet control to the treatment of diabetes.
Thus, when counseling a patient who is undergoing pre-
scription therapy for chemical dependence, these non-
pharmacological interventions should be encouraged.
1) Support group participation is a highly efficient
method of identifying and connecting with others in
recovery. These "self-help" groups exist for those giving up
tobacco (Nicotine Anonymous), alcohol (Alcoholics
Anonymous) and opioids (Narcotics Anonymous). Local
resource directories can be obtained from local or regional
headquarters or from their websites for distribution to
patients (see Table 1).
2) Alcohol and substance abuse treatment clinics exist in
communities throughout the country. The pharmacist
who establishes a relationship with local therapists can
make confident referrals to those clinicians when dispens-
ing a medication for addiction treatment. A pharmacist
who has knowledge of community resources will also be
able to refer for help those concerned about another per-
son's potential chemical dependence. In the case of con-
cerned others, a referral may be made for a formal
intervention or to direct someone to his or her employee
assistance program for intervention and referral.
3) Patients and family members should know that recov-
ery from chemical dependence is bolstered by family
involvement. Family participation can significantly sup-
port a successful addiction recovery.
What do relatives need to know?
In addition to dealing directly with patients receiving
addiction pharmacotherapy, pharmacists may be asked by
others for advice on these matters. The spouse of a chem-
ically dependent patient may have developed patterns of
behavior (called enabling) that have unwittingly sup-
Table 1: Outpatient Addiction Pharmacotherapy
Drug of Abuse Prescription Medication Usual SIG Notes Support Systems
Tobacco a) Nicotine Substitution
NTS1 
Polacrilex gum
Nasal spray
Inhaler
Lozenge
b) Buproprion SR
a) various dosing protocols.
b) 150 mg once daily × 3 days 
then; 150 mg B.I.D.
a) Stop tobacco use before initiating 
treatment
b) Contraindicated in patients with a 
history of bulimia, anorexia nervosa, 
seizure, or currently taking an MAOI 
or another product containing 
buproprion.
Nicotine Anonymous http://
www.nicotine-anonymous.org
American Lung Association http://
www.lungusa.org
American Cancer Society http://
www.cancer.org
American Heart Association http://
www.americanheart.org
Alcohol a) Disulfiram
b) Naltrexone
c) Benzodiazepines
a)500 mg once daily × 1 – 2 weeks, 
then 250 mg P.O. once daily
b)50 mg P.O. once daily.
c) dose varies on the basis of the 
specific agent, level of alcohol 
tolerance, history of past 
withdrawal, and presenting 
symptoms of withdrawal.
a) Stop before and avoid all alcohol 
use while taking this prescription. 
Contraindicated in patients with 
severe myocardial disease or 
coronary occlusion. Punishment 
when people drink.
b) Reduces the "high" from alcohol
c) For detoxification only.
Alcoholics Anonymous (A.A.) http://
www.alcoholics-anonymous.org
Alanon, Alateen http://www.al-
anon.org
Rational Recovery http://rational.org
Local resources for alcoholism 
treatment; groups and family therapy.
Opioids a) Naltrexone
b) Methadone
c) LAAM2 
d) Buprenorphine
The use of other opioids for the 
treatment of opioid dependence is 
a violation of federal law.
a) 50 mg P.O., once daily.
b) 20 – 120 mg P.O., once daily.
c) 80 – 100 mg P.O., every other 
day.
d) 4 to 16 mg/day sublingually for 
maintenance.
a) Will precipitate withdrawal if 
taken within 7 to 10 days of last 
opioid use.
b & c) Use for maintenance and 
detoxification tightly regulated by 
FDA
d) Sublingual tablet approved by 
FDA for medical withdrawal and 
maintenance. C-III drug.
Narcotics Anonymous (N.A.) http://
www.na.org
Naranon http://www.naranon.com
Buprenorphine subscribers: http://
buprenorphine.samhsa.gov
Local resources for substance abuse 
and addiction treatment and group and 
family therapy.
1 Nicotine Transdermal System 2 L-alpha-acetyl-methadolHarm Reduction Journal 2004, 1 http://www.harmreductionjournal.com/content/1/1/3
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ported the substance abuse of the husband or wife. When
the opportunity arises, the pharmacist should recom-
mend spousal participation in a support program
designed for their needs. These are Al-Anon and Nar-Anon
for the spouses of alcohol and opioid dependent patients,
respectively. The goal of this referral is to help the spouse
recognize enabling behaviors and to stop them. Just as the
affected individual is consciously unaware of the insidi-
ous development of chemical dependence, the spouse
often fails to realize that his or her behavior is deeply
enmeshed in the behavior of the dependent partner.
Enabling is recognized as a characteristic of co-depend-
ency under the family disease view of substance use disor-
ders [29]. The therapeutic approach to the co-dependent
person is to help him or her detach from the intricacies of
the dependent person's disease and treatment. While this
may seem paradoxical to the notion of a family disease
model of addiction, only by detaching can the spouse
work to reduce their own emotional distress and improve
their own coping. As the spouse becomes healthier, the
addicted partner is forced to confront his or her issues
directly without the co-dependent person running inter-
ference, taking partial responsibility, and softening the
impact of the disease.
Parents of drug using teens are another group who may
ask the pharmacist's advice on matters of substance abuse
and addiction. On-line resources can address many ques-
tions of pharmacological fact; however some websites
proselytize the drug culture and provide biased and non-
factual material. In contrast, the National Institute on
Drug Abuse (NIDA) maintains a website that offers valid
factual information on commonly abused drugs. In addi-
tion, the site http://www.nida.nih.gov provides access to
publications in a variety of formats from newsletters to
condensed "fact sheets" that can be downloaded, printed,
and offered to pharmacy patrons.
Parents have a legitimate fear that drug abuse can disrupt
their child's healthy development. Unfortunately, the dis-
tinction between normal adolescent inquisitiveness and
pathology, while important, is not easily made. Youthful
experimentation in many areas of life is common and to
be expected. Alcohol and other drugs, especially mari-
juana, are easily accessible to youth but, with the excep-
tion of tobacco, use becomes habitual and hazardous in
only a small percentage. Alcohol, tobacco, and marijuana
in that order appear year after year in surveys of school-
aged populations as the drugs most often experimented
with and used frequently.
The literature on adolescent drug abuse and prevention
suggests several concepts germane to our understanding
of these issues. Two of these are risk factors and protective
factors. As the terms imply, risk factors are aspects of life
that are associated with a greater likelihood of drug abuse,
while protective factors work to reduce the potential for
drug abuse. The research is not clear-cut on these associa-
tions; some factors may work differently in different stages
of life and in different groups of individuals. In addition,
the impact of a risk factor can be mediated by other inter-
vening considerations and some risk factors are co-related
[30]. Generally, the notion of risk and protective factors is
informative in discussions with parents, since risk factors
can be reduced and protective factors enhanced as a
means of intervention [31].
• http://www.nida.nih.gov/Infofax/lessons.html
When parents ask a pharmacist about drug effects, there
may be an underlying and undisclosed concern about
drug use by their child. Thus, the question; "Is marijuana
addictive?" may be heard as; "Is my child addicted to mar-
ijuana?" This particular question about the nature of mar-
ijuana is perhaps one of the most confusing. Since
discontinuation of marijuana even after prolonged heavy
use is not associated with a physical withdrawal syn-
drome, few people acknowledge its addictive potential.
However, when addiction is defined by compulsive use,
loss of control, and continued use despite problems, the
reality of addiction to marijuana is evident. As discussed
earlier, the road to addiction traverses some predictable
territory.
While some amount of experimentation is normative for
adolescents, parents should be concerned when they find
evidence of the following signs of progression:
a. Using drugs alone
b. Stockpiling drugs
c. Changing friends
d. Willingness to take increasing risks to use drugs
e. Using drugs at inappropriate times
f. Becoming defensive when asked about drugs or drug use
practices
g. Carrying drugs
CRAFFT is a screening questionnaire designed specifically
for adolescents [32]. It asks these questions:
Have you ever ridden in a Car driven by someone (includ-
ing yourself) who was high or had been using alcohol or
drugs?Harm Reduction Journal 2004, 1 http://www.harmreductionjournal.com/content/1/1/3
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Do you ever use alcohol or drugs to Relax, feel better
about yourself?
Do you ever use alcohol or drugs while you are by yourself
(Alone)?
Do you ever Forget things you did while using alcohol or
drugs?
Do your Family or Friends ever tell you that you should
cut down on your drinking or drug use?
Have you ever gotten into Trouble while you were using
alcohol or drugs?
A score of 2 or more "yes" responses is a positive screen.
Parental action is warranted when such signals are seen.
Parents should act swiftly to change those things that can
be changed in both the risk and protective dimensions. Of
course, a preferred strategy would be for parents to be con-
sistently and supportively engaged in the lives of their
children so that positive bonds are created during child-
hood and carried into the adolescent years of their chil-
dren's lives.
Drug effects
Psychoactive drugs can be classified into three broad cate-
gories, 1) depressants, 2) stimulants, and 3) psychedelics.
Some details of the effects of popular drugs in these cate-
gories can be found in Table 2 (see Additional File 1) and
in more detail at the NIDA website identified earlier.
While the details of street drug pharmacology are fascinat-
ing and sometimes critical, the overarching basic actions
characteristic of each category are sufficient to address
many inquiries. Furthermore, drug users themselves can-
not be certain that the drug they bought is the drug they
set out to purchase. The illicit drug market provides no
quality assurance, no guarantee of purity, or even the
capacity of the buyer to ascertain the qualitative (much
less the quantitative) properties of the material purchased.
These uncertainties reduce critical care of overdose victims
to symptomatic and supportive responses and antidotal
therapy on trial and error basis [33].
Depressant drugs like alcohol, heroin, baribiturates, ben-
zodiazepines, anesthetics, solvents, and gammahydroxy-
butyrate (GHB) cause sedation. The initial effect may be
liberating and disinhibiting, but as the blood level rises,
the user becomes more impaired and exhibits signs of
muscle incoordination, difficult speech, unsteady gait,
and a general unawareness of the surroundings. In a toxic
overdose the person may succumb to the potentially fatal
effects of respiratory depression and cardiovascular col-
lapse. These agents produce addiction with concurrent
physical dependence. Abrupt discontinuation after pro-
longed, frequent use of heavy doses could require medical
intervention with a dose tapering approach sometimes
involving the substitution of an alternative sedating med-
ication, such as a benzodiazepine. This latter event, called
withdrawal, is the result of biphasic action; the initial
sedating effect of the drug is followed by rebound agita-
tion that is opposite and proportional to the initial action
and with the execption of opioids could progress to
seizure.
Stimulant drugs like cocaine, amphetamine (and other
phenethylamines), and caffeine produce excitation during
the action phase of the biphasic effect. The initial effect at
a low blood level enhances clarity of thought and
increases performance speed without increasing errors. As
the blood level rises, these enticing effects are followed by
confusion, disorganization of thinking, and performance
errors. The physical effects of overdose include paranoid
psychosis along with potentially fatal cardiovascular acci-
dents and seizure. Since there is no physical dependence,
there is no pharmacological intervention for detoxifica-
tion; however, profound rebound depression is a predict-
able aftermath of heavy stimulant abuse.
Psychedelics like lysergic acid diethylamide (LSD), mari-
juana, and methlyene-dioxy-methamphetamine (MDMA,
"ecstasy") distort normal perceptions through mecha-
nisms that are not entirely clear. The psychoactive effects
of cannabis are thought to be mediated through specific
cannabinoid receptors in the brain located in regions
responsible for cognition, memory, and movement. These
receptors respond to the endogenous ligand anandamide
and are present in only low levels in the brain stem, which
may explain the lack of lethality of cannabinoids [34].
LSD and MDMA are not active at the cannabinoid recep-
tor, and no cross tolerance between cannabis and these
agents is seen. LSD and MDMA share structural features
with serotonin, and it appears to be the affinity of these
agents for 5-HT2 receptors that correlate with psychedelic
potency. These receptors are highly concentrated in the
cerebral cortex, and the effects of these agents on percep-
tual and cognitive functions are likely to be mediated pre-
dominantly through this brain region [35]. Evidence also
exists that ties 5-HT2 receptors to the function of the locus
coeruleus (LC). The LC receives an abundance of somatic,
visceral, and other sensory inputs that converge from all
regions of the body. The LC has been likened to a novelty
detector [36]. The response of LC neurons to sensory stim-
ulate is enhanced by LSD.
While neuroanatomy and the geography of the brain are
understood in great detail, a psychodynamic model as it
relates to psychedelic drug action may be helpful in this
context. Freud developed concepts of id, ego, and super-Harm Reduction Journal 2004, 1 http://www.harmreductionjournal.com/content/1/1/3
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ego to explain the internal conflict of the human psyche.
The unconscious id represents our primal impulses, the
partially conscious superego represents the internaliza-
tion of societal rules, high moral values, and desire to act
honorably, and the conscious ego mediates the conflict
between them. Ego also functions to organize our sense
perceptions into a reality shared with others in our world,
particularly the senses of time, person, and place. Ego has
also been called the guardian of the unconscious mind. To
use a computer metaphor, the brain is the hardware and
the mind is the software.
The senses are distorted and the perception of reality
changes when ego function is disturbed by psychedelic
drugs. This may be fascinating at low intensity, but as the
effect increases the fascination may give way to fear. An
individual who then attempts to resist the drug effect may
move into a state of emotional conflict thought to be the
basis of a "bad trip" [37]. Although some psychedelic
agents, in particular MDMA, can induce dose related tox-
icity (see Table 2, Additional File 1) many of the acute
adverse effects of psychedelic drugs are related to behav-
iors resulting in accidental injury or fatality.
Recently emerging "drugs of abuse" include gamma-
hydroxy-butyrate (GHB) and methylene-dioxy-metham-
phetamine (MDMA, "ecstasy"). These agents have
received substantial attention in the media. Although the
number of users of these agents is small compared to the
more commonly abused alcohol and marijuana, parents
may have concerns and pharmacists should have suffi-
cient knowledge to discuss them at community events.
GHB is best understood as a depressant agent similar in
effect to ethanol and benzodiazepines. Street names
include liquid X, salty water, scoop, and soap. It is most
frequently sold and ingested as a liquid. The pharmacol-
ogy of GHB was the topic of a recent thorough review of
the scientific literature [38]. GHB is a short chain fatty acid
naturally occurring in mammalian tissue and functioning
as a neurotransmitter or neuromodulator at GHB recep-
tors in the brain. The effects of GHB are evident within 15
to 30 minutes after ingestion of a little as 10 mg/kg with
peak levels being reached in 25–45 minutes. Sedative
effects are seen with doses in the 20–30 mg/kg range and
60 mg/kg and higher doses can produce coma.
In comparison to alcohol, there are important similarities
and differences. On one hand, GHB exhibits cross-toler-
ance with ethanol and produces synergistic effects when
ingested concurrently. This synergism has earned GHB the
reputation as a "date rape" drug along with the benzodi-
azepine rohypnol. GHB mixes easily with alcoholic drinks
and can quickly and surreptitiously be added to an unsus-
pecting victim's glass or bottle. GHB also alleviates alco-
hol withdrawal distress.
On the other hand, animal data suggest differences
between GHB and ethanol. Rats trained to discriminate
between GHB and saline do not substitute ethanol. In
other words, these animals recognize a difference between
ethanol and GHB. On a cellular level, there appears to be
no overlap between the two agents. Ethanol has been
shown to have significant activity at GABAA and NMDA
receptors while GHB shows only weak effects on NMDA
receptors and is devoid of GABAA effects. Pre-clinical stud-
ies support a conclusion that physical dependence is more
difficult to induce with GHB than with ethanol, and GHB
withdrawal distress appears to be less severe than that of
alcohol.
In contrast to ethanol, GHB induces sleep without dis-
rupting the sleep cycle. This ability to induce a physiolog-
ical sleep may be exploited therapeutically in the
treatment of narcolepsy. It is suggested that patients with
this disorder suffer with extreme daytime sleepiness and
related symptoms because they experience profound sleep
disturbances throughout the night. GHB reduces daytime
symptoms of narcolepsy by eliminating the sleep distur-
bances and restoring a more natural sleep pattern. By
comparison, alcohol induced sleep is unnatural in that
suppression of REM and slow wave sleep leaves the indi-
vidual unrested and unstable the next day.
It is the ability of GHB to induce slow wave sleep that
appears to explain its attraction for body builders. Growth
hormone is released from the anterior pituitary during
this stage of sleep. Despite its use for this purpose a recent
literature review produced no empirical evidence that
GHB-induced hormone release yielded any increase in
muscle mass.
The Food and Drug Administration banned the sale of
GHB in 1990. Although the chemical is being developed
for medicinal use by legitimate pharmaceutical compa-
nies, the current supply of GHB for recreational use is
from illegal sources. Liquid samples of GHB obtained in
an illicit market show large variations in concentration. At
best, users are guessing the ingested dose even when the
volume is carefully measured. The rapid absorption and
inaccurate dosing have led to cases of acute poisoning,
especially when GHB is taken in combination with alco-
hol or another sedative agent.
Seizures of illicit MDMA by the Drug Enforcement
Administration have risen sharply in the past two years,
consistent with reports of increasing "ecstasy" use among
teens. The use of this drug, which has many street names
in addition to the more common "ecstasy", has beenHarm Reduction Journal 2004, 1 http://www.harmreductionjournal.com/content/1/1/3
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closely tied to dance parties called "raves." These are often
promoted as alcohol free events, giving parents a false
sense of security that there is no affiliated drug use. Rave
participants are likely to be teens, and the events are com-
monly held in open-air locations or in large indoor ven-
ues such as warehouses. A rave may go on late into the
night and may not break up until sunrise.
The scientific literature is at odds with some popular con-
ceptions of MDMA safety. One trendy website can be
found at http://www.dancesafe.org. An examination of
this homepage reveals links to other sites that provide
information biased toward favorable perspectives on
MDMA use and that downplay concerns about MDMA
toxicity. The sense that one gets from information availa-
ble at this site disagrees considerably with information
from government sources http://www.nida.nih.gov and
from reports in scientific journals.
A recent review of the medical literature summarizes the
scientific data on MDMA effects [39]. MDMA is an
amphetamine structure as its name implies, but the added
moiety substantially alters the pharmacological response.
The effect is more akin to psychedelic than to stimulant
agents. Thus, the more striking response is that of a psych-
edelic with stimulant overtones. Effects on the neuro-
transmitter serotonin are at the center of concern over
MDMA, both in terms of psychoactive response and toxic-
ity. Animal studies reveal that the most likely mechanism
of action is enhancement of serotonin neurotransmission
through blockade of reuptake after its release. However,
this does not constitute an entire explanation since the
recent selective serotonin reuptake inhibitor (SSRI) anti-
depressants do not induce the same effects nor display
similar toxicity as MDMA and there is no evidence of their
abuse. Like other psychedelic agents, MDMA acts selec-
tively at 5-HT2 (5-hydroytryptamine type 2) receptors
[40]. This differential serotonergic action, coupled with
the stimulant qualities of the drug, make MDMA particu-
larly suited to the rave scene and its participants.
The main appeal of MDMA appears to be its ability to pro-
duce a sensation of attachment and connection to others.
The drug produces a sense of emotional and physical well-
being, a desire to communicate with others, and a strong
feeling of belonging to the group [41]. Individuals under
the influence of the drug want physical contact. For young
people struggling with the angst of self-identity and group
membership, these effects fulfill a deep need common
among adolescents.
The use of MDMA comes with risks. A particularly trouble-
some pattern of toxicity results from an overload of sero-
tonergic activity which may be aggravated by the rave
conditions, i.e., crowded environment, high ambient tem-
perature, loud sound, and possible dehydration. Hyper-
thermia is a central feature of this toxicity. Body
temperatures as high as 43°C (109°F) have been reported
[39]. Fatalities from MDMA are related to this extreme
body temperature that can produce hyperthermic sei-
zures, rhabdomyolysis (muscle breakdown), dissemi-
nated intravenous coagulation, and renal failure. Other
vexing, but less critical, undesirable effects include brux-
ism (tooth grinding), trismus (jaw tightening), nausea,
blurred vision, and tremor. Lollipops and baby pacifiers
are the paraphernalia used by rave participants to reduce
the dental complications of the drug effects.
In addition to the acute toxic and undesirable effects of
MDMA, users are at risk of after-effects and long-term neu-
rotoxicity. The hangover effects of MDMA use include
lethargy, anorexia, decreased motivation, and, in some
cases, anhedonia (loss of feeling of pleasure). More trou-
bling than these short-term effects is the growing body of
literature that points to long-term dysfunction that may
be caused by damage to serotonin neurons in the central
nervous system. Evidence from laboratory studies in ani-
mals, brain imaging in humans, and clinical observations
of heavy "ecstasy" users by and large are consistent with
serotonergic neuro-degeneration. Animal studies in vari-
ous species show MDMA induced degeneration of sero-
tonergic axons with repeated administration, a decrease in
concentrations of both serotonin and its metabolite, 5-
hydroxy-indole-acetic-acid (5-HIAA), and a disturbing
reorganization pattern of serotonin neurons in which
projections to distant sites are pruned back with a con-
comitant overgrowth (sprouting) to proximal sites. Posi-
tron emission tomography (PET) studies in humans
reveal dysfunction in 5-HT transport systems in heavy
"ecstasy" users vs. controls weeks to years after use. The
severity of dysfunction correlates with the extent of use
[42]. Fear of brain atrophy among "ecstasy" users has
arisen from studies using proton magnetic resonance
spectroscopy [43,44]. Clinical evidence suggests that
changes in mood and behavior among heavy "ecstasy"
users are consistent with serotonergic dysfunction.
Although the measure of "heavy" use encompasses a wide
range (30 to 1000 incidents of use), the heavy users seem
to be those engaged in weekly exposure and multiple
doses at each incident. Disruptions in memory, executive
function (planning and making choices among alterna-
tives) and learning are common findings in studies of this
group. Sleep disturbances have been noted along with
mood depression, anxiety, and increased impulsiveness.
The usual single dose of MDMA in a recreational setting is
75 to 150 mg. The effects begin within 20 to 40 minutes,
with the initial experience being stimulation. Emotional
changes and subjective effects follow and last three to four
hours. As the effects of the first dose wane, users often takeHarm Reduction Journal 2004, 1 http://www.harmreductionjournal.com/content/1/1/3
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a "booster" dose to keep the experience going. MDMA is
eliminated from the body through liver metabolism and
urinary excretion of metabolites. Current urine testing for
drugs of abuse does not identify MDMA specifically,
which is a shortcoming for clinicians treating abusers of
this drug. It is possible to adjust the testing protocol to
detect MDMA on an amphetamine screen by lowering the
cut-off level. This will produce a false positive for amphet-
amine but will result in the sample being sent for a second
assay where MDMA can be identified as the substance
present.
There is no legitimate source of MDMA in the United
States. Thus, users must rely on an illicit distribution net-
work. Most of the MDMA sold in the U.S. comes from
European production sites. The buyer is at an extreme dis-
advantage in that he or she cannot be certain of the con-
tents of any particular product sold under the many
"brand" names of "ecstasy" tablets. Chemical analysis of
purported MDMA samples makes the point. The dance-
safe.org website provides a link to lab results of MDMA
tablet testing. A posting of 100 samples (from July to
November 2001) revealed that 53% of the samples were
unadulterated MDMA (no quantitative data available),
13% of the samples were MDMA plus other psychoactive
ingredients, with ketamine and caffeine being the most
prevalent, and the remaining 34% of the samples con-
tained no MDMA, but were made up of a variety of chem-
icals including dextromethorphan, acetaminophen,
caffeine, ketamine, ephedrine, and methamphetamine,
either alone or in combination.
Building and using a local list of resources
The local Yellow Pages lists substance abuse and addiction
services under the following headings: 1) Alcoholism &
Drug Abuse Information & Treatment Centers, 2) Drug
Abuse & Addiction Information & Treatment Centers, and
3) Information & Referral Services Drug Abuse & Addic-
tion. An on-line search of http://www.bigyellow.com will
yield a listing under these categories by state.
Treatment resources can be divided into several categories
in line with the continuum of care concept applied to
addiction therapy. The continuum of care concept is to
initiate treatment with the least intrusive intervention that
will succeed for the patient. Accordingly, treatment
options range from outpatient counseling and education
programs to intensive inpatient experiences. The most
urgent and severe treatment needs occur when a chemi-
cally dependent person initiates abstinence and begins to
experience withdrawal distress. This is most likely to occur
among those addicted to depressant drugs such as alco-
hol, opioids, anti-anxiety agents, and soporifics. These
agents produce a state of physical dependence and abrupt
discontinuation is physically painful, and in the case of
alcohol and sedative drugs, potentially fatal.
Building a readily available list of local resources is help-
ful in that people are most likely to accept a referral in
their time of need. A person who expresses a desire for
help today may have been unwilling to accept a referral
yesterday and by tomorrow the urgency may have passed.
Research indicates that individuals go through stages in
their approach to making life changes. These stages of
change can be determined by questioning and the inter-
vention geared to the person's readiness for change [45].
The five stages are conceptualized as 1) pre-contempla-
tion, 2) contemplation, 3) preparation, 4) action, and 5)
maintenance. A clinical strategy called "motivational
interviewing" has been built around this change theory
[46].
Table 4 presents basic elements of the readiness or stage of
change theory, intervention approaches, and some sug-
gested language for talking with patients in each stage.
Levinison et al. offer a very practical guide for employing
this model in patient oriented clinical practice [47].
Patients rarely succeed on their first attempt at change.
One need only consider something in his or her own life
that needs to change to realize that old patterns die hard.
Table 3: Risk and Protective Factors Related to Adolescent Drug Abuse*
Risk Factors Protective Factors
Chaotic home environment Strong and positive bonds with family
Parental substance abuse or mental illness Parental monitoring
Ineffective parenting Clear rules of conduct that are consistently enforced within the family
Affiliations with deviant peers Involvement of parents in the lives of their children
Adolescent's perception of approval of drug-using behaviors in family, 
work, school, peers and community environments
Adoption of conventional norms about drug use
Lack of nurturing Bonds with other pro-social institutions such as school, and church
Failure in school performance Success in school performance
* Table adapted from NIDA infofax "Lessons from Prevention Research"Harm Reduction Journal 2004, 1 http://www.harmreductionjournal.com/content/1/1/3
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Thus, pharmacists should anticipate that advice given
once needs to be reinforced with reminders over time. In
addition, the stage of change theory warns of relapse, and
predicts that people cycle through the stages several times.
The individual should re-engage the behavior modifica-
tion with a renewed commitment to change, a greater
level of understanding about themselves and their prob-
lem, and an increased intensity of resolve to improve his
or her life. The pharmacist can help the patient recognize
that in order to "relapse" one has to have succeeded in ini-
tiating the change in the first place. The pharmacist can
periodically instill optimism by pointing out that the
individual is farther along the path of permanent change
than they were initially.
Collegial response
When a pharmacist develops chemical dependence, the
whole profession suffers. As members of a professional
community, our individual image is affected by the
behavior of other pharmacists. In some respects our repu-
tation rests on someone else's shoulders. Professionals
have a self-regulating duty. Individual pharmacists and
the licensing boards that regulate the profession have eth-
ical, moral, and legal responsibilities to protect the public
safety and to ensure the viability of the profession.
Over the past 25 years, alcohol and other drug abuse in
the workplace were found to be the single largest contri-
bution to the problem of employee impairment and lost
productivity. In its nascent form, the employee assistance
program (EAP) was a job-based alcoholism program. It
has since grown in scope and scale to handle a host of
employee problems. The success of the EAP is attributed
to the fact that it offers constructive techniques for dealing
with employees' problems in ways that are oriented
toward conflict reduction in the workplace [48]. The EAP
has emerged as a friend to both employer and employee,
winning the support of both management and labor.
As early as 1982, the American Pharmaceutical Associa-
tion adopted policies that "...pharmacists should not prac-
tice while subject to physical or mental impairment due to
the influence of drugs – including alcohol – or other
causes that might adversely affect their abilities to func-
tion properly in their professional capacities" and favor-
ing a rehabilitative approach to the problem of impaired
Table 4: Categories of Treatment Modalities For Those with Substance Abuse and Chemical Dependence
Modality Duration and characteristics of care Clientele
Detoxification Alcohol – 3 to 5 days inpatient. Usually with 
benzodiazepine tapering. Opioids – 10 to 180 days 
outpatient using methadone or buprenorphine.
Those displaying or at risk for severe alcohol or 
opioid withdrawal distress.
Intensive Outpatient Therapy (IOP) 3 to 5 weeks. Patients live off-site and attend 
therapy for 4 to 6 hours per day.
Those recently discharged from detoxification 
protocols or who require aggressive initiation of 
therapy
Individual, Group, and Family 
Outpatient Therapy
6 to 24 months. Clients attend hourly sessions 
once a week to discover and deal with issues 
related to their disease. The least intrusive 
modality for patients with chemical dependence.
Those discharged from IOP and need continued 
recovery support (most patients) and those 
deemed able to establish sobriety with minimal 
intervention.
Education and Information Programs 4 to 6 weeks. Classes run in cycles providing 
information about substance abuse and its varied 
consequences
Substance abusers not diagnosed chemically 
dependent who may respond to information and 
reason
Therapeutic Community 12 to 36 months. Clients reside at the facility 
entering with no status and earning privileges as 
their recovery matures
Individuals are often court referred or otherwise 
coerced into treatment by parents or authorities. 
Clients have usually failed more conventional 
therapeutic approaches.
Inpatient Treatment Center Typically 1 to 4 weeks (although some individuals 
may stay longer). Live-in facility where patients are 
steeped in recovery activities and philosophy. 
Alcohol or opioid detoxification may be done on 
premises.
Chemically dependent patients with or without 
physical dependence. Clients may have been 
unsuccessful in outpatient treatment or are first 
time admissions deemed to be unlikely to succeed 
in outpatient care.
Half-Way facility 1 year or longer. Recovery centered housing 
where housemates gain mutual support from each 
other's sobriety. Many are based on 12-step 
recovery traditions
Clients in recovery who have been unable to 
sustain sobriety in standard community housing or 
who are homeless.
Opioid Maintenance in certified 
treatment programs
Greater than 180 days of daily oral dosing with 
methadone or buprenorphine, or every-other-day 
dosing with LAAM or buprenorphine.
Patients who are > 18 years of age, have at least a 1 
year history of addiction, and are physically 
dependent on an opioid.
Opioid maintenance in office based 
practices
Buprenorphine prescribed by authorized primary 
care physicians and dispensed by local pharmacies.
Patients who are deemed by the physician to be in 
need of pharmacotherapy for opioid dependence.Harm Reduction Journal 2004, 1 http://www.harmreductionjournal.com/content/1/1/3
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pharmacists [49]. These policies reflect the recognition
that the problems of substance abuse and addiction are at
least as prevalent in the health professions (including
pharmacy) as they are in the general population [50,51].
When a pharmacist observes a colleague practicing while
impaired, she or he has an ethical duty to act. In some
states, this means a report must be made to the Board of
Pharmacy. In other states, the report is made to a collegial
assistance program, most-typically called the Pharmacist
Recovery Network (PRN), or to an "umbrella" assistance
program serving a number of, or all, health professions.
Such programs have been built around the EAP model. A
rehabilitative approach is superior to a punitive approach
in the discovery and treatment of impaired pharmacists
[52]. Failure to act ignores the problem, endangers the
public health, and prolongs the period of dysfunction for
the affected pharmacist. These programs may use recovery
contracts that usually employ urine testing for drugs of
abuse as a means of supporting recovery. Recovery rates
exceeding 80% are anecdotally reported for such
programs.
Additional pharmacy roles
In addition to offering the categories of treatment prac-
tices described in this text, pharmacists can speak in
schools, churches, and other community organizations in
need of substance abuse education. Pharmacists also pos-
sess the academic credentials to teach courses at commu-
nity colleges and universities on the topic of substance
abuse pharmacology. Additionally, they can conduct staff
training on this topic at addiction treatment centers in
their locale in the process of strengthening their therapeu-
tic associations with those entities. As his or her knowl-
edge of substance abuse increases and becomes more
refined, the pharmacist can transpose this expertise into a
consult service to these same centers where staff members
struggle to understand the complexities of addiction
pharmacotherapy.
Summary
Pharmacists are accessible, knowledgeable, and respected
health professionals. The frontier of practice has been rap-
idly expanding into areas of clinical pharmacotherapy,
information services, disease state management, and
other unique niches in the health services delivery envi-
ronment. However, the community pharmacist continues
to be the most visible pharmacy practitioner with whom
the public interacts on a daily basis. Taken in whole meas-
ure, community pharmacists represent a largely untapped
public health resource.
The country is rapidly moving forward with policies and
programs that will expand access to drug abuse treatment
services. Treatment of these problems is moving into envi-
ronments of primary care and pharmacists will become
directly involved in this process. The time has come for
the pharmacy profession to seize the opportunities that
are emerging as these changes come about.
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Additional material
Table 5: Stages of Change and Stage Appropriate Intervention
Stage of Change Characteristic Intervention Approach Suggested Language
Pre-contemplation Not thinking about change. Discuss risks of drug abuse and benefits 
of quitting. Link specific negative 
consequences to drug use. Strongly 
advise quitting.
"What would it take for you to 
consider seeking help?"
Contemplation Thinking about change in next 6 
months but not within 30 days
Discuss immediate benefits of quitting 
to self and loved ones. Emphasize 
health, economic and interpersonal 
payoffs.
"What would it take for you to seek 
help now?"
Preparation Ready to change in next 30 days Discuss strategies and options. Pick a 
change date. Refer to specialist if 
necessary.
"Which option do you think will work 
best for you?"
Action Has initiated and maintained new 
behavior for up to 6 months.
Support decision. Encourage change. 
Discuss pitfalls and common sources of 
failure.
"What do you think will be your 
biggest challenge? How might you deal 
with it?"
Maintenance Quit for more than 6 months Periodic follow-up and continued 
encouragement. Discuss triggers.
"What have you learned about 
people, places, events, and emotions 
that make you want to use?"
Additional File 1
There is one additional file. The filename is Tommasello_Table 2. It is in 
Excel format, and is Table 2 for this paper.
Click here for fileHarm Reduction Journal 2004, 1 http://www.harmreductionjournal.com/content/1/1/3
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